Table 19:
Prostate Cancer Mortality by Participant Age in the ERSPC Trial
| Age, Years | Screening Arm | Control Arm | RR (95% CI) | ARD/10,000 P-YRs, Screen – Control (95% CI) | ||||
|---|---|---|---|---|---|---|---|---|
| PC Deaths | P-YRs | Rate/10,000 P-YRs | PC Deaths | P-YRs | Rate/10,000 P-YRs | |||
| ≤ 54 | 6 | 66,010 | 0.9 | 9 | 64,334 | 1.4 | 0.65 (0.23–1.83) | −0.5 (−1.7 to 0.7) |
| 55–59 | 94 | 378,539 | 2.5 | 144 | 480,748 | 3.0 | 0.81 (0.62–1.15) | −0.5 (−1.2 to 0.2) |
| 60–64 | 106 | 226,339 | 4.7 | 136 | 261,588 | 5.2 | 0.92 (0.71–1.18) | −0.5 (1.8 to 0.7) |
| 65–69 | 99 | 159,355 | 6.2 | 182 | 190,717 | 9.5 | 0.67 (0.53–0.86) | −3.3 (−5.2 to 1.5) |
| ≥ 70 | 59 | 44,402 | 13.3 | 51 | 45,285 | 11.3 | 1.18 (0.81–1.72) | 2.0 (−2.6 to 6.6) |
| Core ages (55–69) | 299 | 764,233 | 3.9 | 462 | 933,053 | 5.0 | 0.79 (0.68–0.91) | −1.0 (−1.7 to −0.4) |
| All ages (50–74) | 364 | 874,644 | 4.2 | 522 | 1,042,672 | 5.0 | 0.83 (0.72–0.94) | −0.8 (−01.4 to −0.2) |
Abbreviations: ARD, absolute risk difference; CI, confidence interval; ERSPC, European Randomized Study of Screening for Prostate Cancer; PC, prostate cancer; P-YR, person-year; RR, relative risk.
Source: Schroder et al, 2012. (55)